نتایج جستجو برای: efavirenz

تعداد نتایج: 2276  

Journal: :The Journal of infectious diseases 2014
Haryes A Funes Nadezda Apostolova Fernando Alegre Ana Blas-Garcia Angeles Alvarez Miguel Marti-Cabrera Juan V Esplugues

BACKGROUND Neurological pathogenesis is associated with mitochondrial dysfunction and differences in neuronal/glial handling of oxygen and glucose. The main side effects attributed to efavirenz involve the CNS, but the underlying mechanisms are unclear. METHODS Human cell lines and rat primary cultures of neurons and astrocytes were treated with clinically relevant efavirenz concentration. ...

2010
Y Zhang A Owen D Egan SF Sarfo

Results The frequency of CYP2B6 516G>T and CYP2A6*9 genotypes were GG 29.8%, GT 44.3%, TT 25.9% and CC 91.6%, AC 8.7%, and AA 0.39%, respectively. Both polymorphisms were statistically associated with efavirenz plasma concentrations. Median plasma concentrations according to CYP2B6 516G>T were 1297, 1833 (P < 0.05) and 2248 (P < 0.001) μg/ml for GG, GT and TT individuals, respectively. Median p...

2013
P. T. Koh J. N. Chuah Meghna Talekar A. Gorajana S. Garg

The aim of this study was to enhance the dissolution rate of efavirenz using solid dispersion systems (binary and ternary). A comparison between solvent and fusion method was also investigated. Solid dispersions of efavirenz were prepared using polyethylene glycol 8000, polyvinylpyrrolidone K30 alone and combination of both. Tween 80 was incorporated to obtain a ternary solid dispersion system....

Journal: :The Journal of infectious diseases 2010
David A Cooper Jayvant Heera James Goodrich Margaret Tawadrous Michael Saag Edwin Dejesus Nathan Clumeck Sharon Walmsley Naitee Ting Eoin Coakley Jacqueline D Reeves Gustavo Reyes-Teran Mike Westby Elna Van Der Ryst Prudence Ive Lerato Mohapi Horacio Mingrone Andrzej Horban Frances Hackman John Sullivan Howard Mayer

BACKGROUND The MERIT (Maraviroc versus Efavirenz in Treatment-Naive Patients) study compared maraviroc and efavirenz, both with zidovudine-lamivudine, in antiretroviral-naive patients with R5 human immunodeficiency virus type 1 (HIV-1) infection. METHODS Patients screened for R5 HIV-1 were randomized to receive efavirenz (600 mg once daily) or maraviroc (300 mg once or twice daily) with zidov...

2016
Andrzej Bienczak Adrian Cook Lubbe Wiesner Adeniyi Olagunju Veronica Mulenga Cissy Kityo Addy Kekitiinwa Andrew Owen A. Sarah Walker Diana M. Gibb Helen McIlleron David Burger Paolo Denti

AIMS Using a model-based approach, the efavirenz steady-state pharmacokinetics in African children is characterized, quantifying demographic and genotypic effects on the drug's disposition. Simulations are also conducted allowing prediction of optimized doses of efavirenz in this population. METHODS We modelled the steady-state population pharmacokinetics of efavirenz in Ugandan and Zambian c...

2010
Sumonmal Uttayamakul Sirirat Likanonsakul Weerawat Manosuthi Nuanjun Wichukchinda Thareerat Kalambaheti Emi E Nakayama Tatsuo Shioda Srisin Khusmith

BACKGROUND Cytochrome P450 2B6 (CYP2B6) metabolizes efavirenz and nevirapine, the major core antiretroviral drugs for HIV in Thailand. Rifampicin, a critical component of tuberculosis (TB) therapy is a potent inducer of CYP enzyme activity. Polymorphisms of CYP2B6 and CYP3A4 are associated with altered activity of hepatic enzyme in the liver and pharmacokinetics resulting in treatment efficacy....

Journal: :Antimicrobial agents and chemotherapy 2010
Gaik H Soon Ping Shen Eu-Leong Yong Paul Pham Charles Flexner Lawrence Lee

Ritonavir-boosted darunavir with efavirenz may be considered a nucleoside-sparing regimen for treatment-naïve HIV-infected patients. However, the pharmacokinetics of this combination administered once daily have not been studied. We conducted a three-period interaction study with healthy volunteers. The subjects were given darunavir at 900 mg with ritonavir at 100 mg once daily for 10 days. Efa...

Journal: :Urological Research 2006

2014
Andrew A Napoli Jennifer J Wood John J Coumbis Amit M Soitkar Daniel W Seekins Hugh H Tilson

OBJECTIVE To assess the potential association of selected antiretrovirals (ARVs), including efavirenz, with suicidality. DESIGN Retrospective analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS), by performing a Multi-Item Gamma Poisson Shrinker (MGPS) disproportionality analysis. METHODS MGPS disproportionality analysis, a technique to identify associations b...

Journal: :The Journal of antimicrobial chemotherapy 2011
Sébastien Gallien Valérie Journot Willy Rozenbaum Patrick Yéni Philippe Morlat Isabelle Poizot-Martin Jacques Reynes Véronique Reliquet Pascale Leclercq François Simon Geneviève Chêne Jean-Michel Molina

BACKGROUND once-daily combinations of efavirenz and two nucleoside analogues are recommended for the treatment of HIV infection. Long-term efficacy and safety data are scarce for the combination of efavirenz, emtricitabine and didanosine. METHODS the ALIZE ANRS 099 trial enrolled 355 adults with plasma HIV RNA levels of <400 copies/mL under a protease inhibitor-based regimen, who were randomi...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید